Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Real-world evidence to guide healthcare policies in oncology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Phospho-ERK levels as predictors for chemotherapy of rectal carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Epigenetic therapy in hematological cancers

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Nasal insulin administration does not affect hepatic glucose production at systemic fasting insulin levels

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mother-child transmission of epigenetic information by tunable polymorphic imprinting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Improvements in overall survival have been observed with the introduction of rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), however, prognostic markers are still needed. Methylation of the death associated protein kinase (DAPK or DAPK1) gene and TP53 mutations are likely to have prognostic value in DLBCL. We have assessed TP53 mutations and allelic DAPK1 methylation patterns in a cohort of 119 DLBCL patients uniformly treated with R-CHOP-like regimens. We found that DAPK1 promoter methylation was associated with shorter overall survival (p=0.017) and disease-specific survival (p=0.023). In multivariate analyses DAPK1 methylation remained as an independent prognostic factor predicting disease-specific survival (p=0.038). When only considering individuals heterozygous for the rs13300553 SNP monoallelic methylation of the A-allele was associated with shorter overall- and disease-specific survival (p<0.001). Patients carrying both DAPK1 methylation and a TP53 mutation had an inferior survival compared to patients carrying only one of these molecular alterations, however, this was borderline statistically significant. Allele-specific DAPK1 methylation patterns were also studied in a cohort of 67 multiple myeloma patients, and all of the methylated multiple myeloma samples heterozygous for the rs13300553 SNP were methylated on both alleles.

OriginalsprogEngelsk
TidsskriftOncotarget
Vol/bind5
Udgave nummer20
Sider (fra-til)9798-810
Antal sider13
ISSN1949-2553
DOI
StatusUdgivet - 30 okt. 2014

ID: 44704822